Gilead needs a big R&D hit. Here's why claims on NASH fall well short of that
For months now, the pressure has been building on Gilead to do something dramatic on the R&D side of the business, with analysts clamoring for the big biotech to buy something or build something big.
So when researchers claimed that they had hit pay dirt data in a mid-stage study of GS-4997 for a blockbuster indication like NASH, the company built it up as encouraging proof of efficacy and significant progress on an important front.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.